AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03926039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sharing decision-making program
Description: Sharing decision-making talks and decision-making assistance tools used in the process
Study NCT04226625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous administration
Study NCT04226625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Volatile administration
Study NCT01722994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyglactin 910 sterile synthetic absorbable suture (Ethicon)
Description: Half of punch biopsy wounds are closed with each absorbablesuture
Study NCT01722994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chromic Gut Sterile absorbable Suture (Ethicon)
Study NCT02440139 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClearRead CT Insight
Description: During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed and the vessel suppressed same slice with the vessel suppressed view as the intervention. The second image, vessel suppressed, will be grayed out until the radiologist move the mouse to the second panel. The radiologist will mark locations. These may or may not correspond to the locations of the CAD markers. As before, the radiologist will assign a level of suspicious to each mark and indicate the need, if any, of an additional diagnostic action (CT Follow-up, Contrast CT, PET-CT, or Biopsy).
Study NCT00640250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens
Description: Disperse blue 106 in PVP, 0.15 mg/cm2 Disperse blue 106 in PVP, 0.050 mg/cm2 Disperse blue 106 in PVP, 0.017 mg/cm2 PVP Negative Control Bronopol in PVP, 0.75 mg/cm2 Bronopol in PVP, 0.50 mg/cm2 Bronopol in PVP, 0.25 mg/cm2 Bronopol in PVP, 0.125 mg/cm2~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours.
Study NCT02722473 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NSE dosage hypothermia arm
Description: There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management between 33° and 37°C.
Study NCT02722473 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: NSE dosage normothermia arm
Description: There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management at 37°C.
Study NCT02869334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial direct current stimulation (tDCS)
Description: Active tDCS, where an extremely weak electric current passes through the brain
Study NCT02869334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Transcranial direct current stimulation (tDCS)
Description: Sham (inactive or placebo) tDCS
Study NCT00158756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™-HepB
Description: GSK Biologicals' combined diphtheria-tetanus-whole cell Bordetella pertussis -hepatitis B vaccine.
Study NCT01949298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental implant placement
Study NCT00158756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: GSK Biologicals' live attenuated human rotavirus vaccine
Study NCT00158756 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix™
Description: GSK Biologicals' live attenuated human rotavirus vaccine
Study NCT00158756 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zilbrix™
Description: GSK Biologicals Kft's combined diphtheria-tetanus whole-cell B. pertussis-hepatitis B vaccine
Study NCT00158756 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Triple Antigen™
Description: Commonwealth Serum Laboratory's (CSL's) combined diphtheria-tetanus-whole cell B. pertussis vaccine.
Study NCT00924001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMF5 Melanoma Reactive TIL
Description: given intravenously over 20-30 minutes (between 1 x 10\^9 and 1 x 10\^11 lymphocytes) after expansion in interleukin-2 and OKT-3
Study NCT00924001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/day x 2 days intravenously
Study NCT00924001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day intravenously x 5 days
Study NCT00924001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 720,000 IU/kg/dose intravenously every 8 hours for up to 15 doses
Study NCT01580410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitomycin C
Description: Given by HIPEC
Study NCT01580410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given by HIPEC
Study NCT01580410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT00158756 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: GSK Biologicals' hepatitis B vaccine
Study NCT01580410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01580410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperthermic intraperitoneal chemotherapy
Description: Undergo HIPEC
Study NCT03706027 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy-3 fractions
Description: Radiation therapy given in a 3 fraction schedule (over 3 days). Total dose is 54 Grays.
Study NCT03706027 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy-5 fractions
Description: Radiation therapy given in 5 fractions (over 5 days). Total dose is 60 Grays.
Study NCT01194245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Study NCT01194245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human hyaluronidase PH20
Study NCT01194245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Study NCT01194245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Study NCT01194245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Study NCT03162133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Study NCT03611998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupation-based programming
Description: Group sessions consisted of specific tasks performed to completion that emphasized skills such as problem-solving, decision-making, frustration tolerance, appropriate pacing, attention, inquiring, sequencing, gathering, organizing, adjusting, responding, enduring, initiating and cooperating. Examples of tasks included projects that the women were specifically interested in learning such as jewelry making, holiday decorations, clay work and other home décor projects. Investigators observed these and other behaviors during the group sessions, and scored individuals using the OTTOS instrument.
Study NCT03707158 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist-led Face-to-Face Cognitive-Behavioral Therapy
Description: Participants receiving face-to-face cognitive-behavioral therapy will participate in therapist-led, office-based or telehealth CBT treatment for up to 16 weeks. Sessions focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.
Study NCT03707158 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital Cognitive-Behavioral Therapy
Description: Participants receiving digital cognitive-behavioral therapy will complete an online, largely self-administered CBT program for up to 16 weeks with 8 modules and adjunctive therapist phone support. Treatment modules focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.
Study NCT03697486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet with different composition
Description: Participants should not eat within the last 10 hours. Participants could drink mineral water up to 2 hours before intervention. Breakfast given is a milk-based formula which has to be finished within 15 minutes, and subjects could only consume 600 mL of mineral water within the next 4 hours after intervention. Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure ghrelin and PYY level. Breakfast given is adjusted to participants' energy requirement. Energy requirement is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity. Different composition of protein, carbohydrate and fat were given to each arm depends on their group.~After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured.
Study NCT00083460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PS-341
Description: Arm 1 a dose of 1.0mg/m2. Arm 2 a dose of 1.3mg/m2
Study NCT00083460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: In cohort 1, a dose of 50mg for cycles 2-8. Cohort 2, 100mg for cycles 2-8. Cohort 3, 150mg for cycles 2-8. Cohort 4, 200mg for cycles 2-8.
Study NCT00083460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: A dose of 20mg for cylces 3-8.
Study NCT00777959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus (MK8669)
Description: Three 10 mg tablets administered daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
Study NCT00777959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Three tablets of matching placebo to ridaforolimus administered daily for 5 consecutive days each week followed by 2 days without matching placebo and on 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
Study NCT00777959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: open-label ridaforolimus (MK8669)
Description: Single dose of three 10 mg tablets ridaforolimus on Day 1, and 50 mg bicalutamide once daily starting on Day 2. On Day 8, patients will begin taking three 10 mg tablets of ridaforolimus daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide once daily for 7 days each week. Treatment will continue until disease progression.
Study NCT01476540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone.
Study NCT01775553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: During Cycle 1, patients will receive either 20 mg/m2 on days 1,2 (if the subject has not received carfilzomib as part another clinical trial within the last 4 weeks) or 56 mg/m2 (if the subject is enrolling in the present study after progression of disease on carfilzomib within the last month - for example subjects enrolled in CMAP compassionate use carfilzomib). Thereafter, all subjects will receive 56 mg/m2 for the remaining doses given Cycle 1 Day 8 onwards. Each cycle is 28 days.
Study NCT03225248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UI05MSP015CT
Description: UI05MSP015CT and Placebo of Gasmotin
Study NCT03225248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gasmotin
Description: Placebo of UI05MSP015CT and Gasmotin
Study NCT01460069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
Study NCT01460069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo pens contain saline and are administered in the same way and volume as (liraglutide) Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
Study NCT00705874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGC-11047 and gemcitabine
Description: Gemcitabine: (Closed to enrollment) 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle. CGC-11047 will only be given on days 1 and 15 of each cycle and will start at dose level -1 (50 mg).
Study NCT00705874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGC-11047 and docetaxel
Description: Docetaxel: (Closed to enrollment) 75 mg/m2 administered IV over 60 minutes every 21 days. CGC-11047 will be administered only on Day 1 of each 21-day cycle and will start at dose level -1 (50 mg).
Study NCT00705874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGC-11047 and bevacizumab
Description: Bevacizumab: 5 mg/kg administered IV once every 14 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
Study NCT00705874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGC-11047 and erlotinib
Description: Erlotinib: 150 mg taken orally every day of each 28-day cycle. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
Study NCT00705874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGC-11047 and cisplatin
Description: Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
Study NCT00705874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGC-11047 and 5-flurouracil / leucovorin
Description: 5-Flurouracil / Leucovorin: Leucovorin 500 mg/m2 IV over 2 hours with 5 - FU 500 mg/m2 IV bolus starting 1 hour into leucovorin infusion weekly for 6 wks, repeated every 56 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
Study NCT00705874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGC-11047 and sunitinib
Description: Sunitinib: 50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle). CGC-11047 will be administered on Days 1 and 8 of a 21 day cycle.
Study NCT01404650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY922: 70 mg/m2 IV over 60 minutes on Days 1, 8, and 15 of each cycle. Treatment cycles will be repeated every 21 days. Patients will be evaluated for response at 6 and 12 weeks and then every 9 weeks (i.e., every 3 cycles) thereafter. Patients may continue treatment until evidence of disease progression.
Study NCT03940079 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: computer-based cognitive game (including 3 training tasks)
Description: First task was short-term memory training. Participants were instructed to memorize different colored circles with ordinal numbers which would disappear later. They triggered correct colored sensor in sequence according to their memory.~Second task was divided attention training. Different colored circles with ordinal numbers would not disappear this time.The participants should trigger correct colored sensor according to their sequence.~Third task was inhibitory function training. There were red and green lights, just like the traffic light, hung up at the upper left of the scene. Red light represented prohibition of triggering the colored sensor, while green light urged to trigger it. Yellow, red, blue and green circles showed up randomly and moved toward the beige region. When the circle came extremely closer to the beige region, the traffic light was randomized to lighten up red or green.The participants should judge and trigger the correct colored sensor.
Study NCT03940079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: computer-based cognitive game (including 3 training tasks)
Description: First task was short-term memory training. Participants were instructed to memorize different colored circles with ordinal numbers which would disappear later. They triggered correct colored sensor in sequence according to their memory.~Second task was divided attention training. Different colored circles with ordinal numbers would not disappear this time.The participants should trigger correct colored sensor according to their sequence.~Third task was inhibitory function training. There were red and green lights, just like the traffic light, hung up at the upper left of the scene. Red light represented prohibition of triggering the colored sensor, while green light urged to trigger it. Yellow, red, blue and green circles showed up randomly and moved toward the beige region. When the circle came extremely closer to the beige region, the traffic light was randomized to lighten up red or green.The participants should judge and trigger the correct colored sensor.
Study NCT02830919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucosamine and chondroitin sulfate combination (Eurofarma)
Study NCT02830919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine and chondroitin sulfate combination (Zodic)
Study NCT02642211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cataract surgery
Description: Eyes (one eye per patient) randomized to either phacoemulsification and intraocular lens insertion or small incision cataract surgery and intraocular lens insertion
Study NCT03115918 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic Duct Stent Placement
Description: Patients will be randomly allocated to either treatment arm to have a PD stent placed.
Study NCT03115918 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Pancreatic Duct Stent Placement
Description: Patients will be randomly allocated to either treatment arm and not receive PD placement.
Study NCT02972229 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 10x(3-5) Gy IMRT
Description: 10x(3-5) Gy IMRT on partial vertebral body for spinal metastases
Study NCT02972229 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 10x3 Gy IMRT
Description: 10x3 Gy IMRT on whole vertebral body for spinal metastases
Study NCT02374541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: The Autism Patient Navigator (APN) will interview families to determine system and individual barriers facing the family at each stage of the care process. The APN will help families to overcome any identified barriers through education, coaching, social support, interpretation or translation, linkage to resources (e.g., for obtaining insurance) or logistical support (e.g., scheduling appointments, providing reminders, arranging transportation), in order to ensure timely diagnostic evaluation / eligibility determination; educate the family about autism, tests and treatments; and offer psychosocial support.
Study NCT02118519 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Mesenchymal Stem Cells
Description: Comparison of clinical outcomes of patients injected by mesenchymal stem cells only with patients injected with mesenchymal stem cells supported by platelet lysate
Study NCT06246747 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In clinic physical therapy
Description: Patients visit the clinic to receive traditional physical therapy treatment
Study NCT06246747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In clinic physical therapy
Description: Patients visit the clinic to receive traditional physical therapy treatment
Study NCT06246747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation only
Description: Patients receive remote treatment using the Wizecare platform
Study NCT00183014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Lifetime Fitness Program
Description: A series of 4 weekly 1-hour group discussion sessions that utilize attribution retraining techniques from the field of motivational psychology in combination with behavioral strategies based in social cognitive theory; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
Study NCT00183014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise class
Description: 1-hour exercise class aimed at increasing strength, flexibility and endurance; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
Study NCT00183014 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise class
Description: 1-hour exercise class aimed at increasing strength, flexibility and endurance; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months